Moreover, the prognostic value of BRAF mutations has been confirmed in patients with CRC treated with specific chemotherapy regimens in clinical trials evaluating a combination of cetuximab with chemotherapy. The gene discussed is BRAF; the disease is colorectal carcinoma.